1xbet 한국., Ltd.

1xbet 한국., Ltd. (Otsuka) and Ai-BrainScience Inc. announce that MIREVO_®, a program for neuropsychological testing to support medical treatment of dementia, has become 1xbet 한국 first Software as a Medical Device (SaMD) in 1xbet 한국 field of of dementia to obtain national health insurance coverage as of January 1, 2025. Marketing of 1xbet 한국 product in Japan began today.

With 1xbet 한국 desire for early detection of dementia, testing methods using new technologies are being developed. MIREVO is a neuropsychological testing program that uses eye tracking technology. 1xbet 한국 test can be easily conducted and results can be obtained in approximately three minutes using 1xbet 한국 MIREVO app on a tablet. By having 1xbet 한국 test subject focus on 1xbet 한국 correct areas in response to 1xbet 한국 questions displayed on 1xbet 한국 screen, data is automatically scored. This allows for a quantitative and objective evaluation, which is not dependent on 1xbet 한국 examiner's knowledge or experience.

In a clinical study conducted on subjects with diagnosed dementia and o1xbet 한국r subjects (including cognitively normal subjects and subjects with suspected mild cognitive impairment), MIREVO showed a correlation between test scores from this program and 1xbet 한국 overall Mini Mental State Examination (MMSE) as 1xbet 한국 primary endpoint. 1xbet 한국 secondary endpoint was a reduction in examiner burden compared to 1xbet 한국 MMSE, and here a reduction in examiner burden was confirmed in comparison with 1xbet 한국 MMSE.

MIREVO is expected to expand 1xbet 한국 options for neuropsychological testing and help in 1xbet 한국 early detection of dementia through use of eye tracking technology.

By developing diagnostic businesses in addition to its pharmaceutical business, Otsuka continues efforts to provide comprehensive options in 1xbet 한국 treatment of dementia and aims to become a total healthcare company addressing challenges society faces as a whole.